Trajectory of cardiac troponin T following moderate-to-severe COVID-19 and the association with cardiac abnormalities

Table 2 Measurements of cardiac structure and function in patients with high sensitivity cardiac troponin T (hs-cTnT) < 5 ng/L and ≥ 5 ng/L at 3-month follow-up

	hs-cTnT < 5 n = 39	hs-cTnT ≥ 5 ng/L n = 150	P-value	Adjusted P-value (Age + Sex + CVD*)
Left ventricular mass index (g/m²)	60 ± 13	73 ± 18	0.001	0.03
Left ventricular end-diastolic volume index (ml/m²)	50 ± 9	53 ± 14	0.21	0.26
Left ventricular ejection fraction (%)	58 ± 4	58 ± 6	0.39	0.69
Left ventricular global longitudinal strain (%)	19.9 ± 1.6	19.1 ± 2.4	0.10	0.21
Left atrial volume index (ml/m²)	24 ± 7	27 ± 9	0.06	0.59
E / e`	8.0 ± 0.5	8.4 ± 0.2	0.01	0.53
Right ventricular basal diameter (cm)	3.5 ± 0.6	3.8 ± 0.5	0.02	0.19
Tricuspid annular plane systolic excursion (cm)	2.4 ± 0.3	2.4 ± 0.3	0.71	0.76
Right ventricular free wall strain (%)	26.4 ± 2.8	25.8 ± 4.2	0.46	0.57
Estimated systolic pulmonary arterial pressure (mmHg)	25 ± 6	23 ± 9	0.34	0.036
Myocardial scar (Late gadolinium enhancement, n = 58)	1 (6%)	11 (27%)	0.07	0.58
Myocardial scar volume (%)	1.74	2.70 ± 1.75

Reported as mean ± SD or number (%). P-values are calculated from logistic regression
*Cardiovascular disease

ISSN: 1471-2261